Page 182 - Drug Class Review

Page 121 of 205
Drug Effectiveness Review Project

placebo 74.0 61 96% 4% 0% 19.8

donepezil 10 mg 73.4 61 96% 1% 3% 19.35 Secondary Outcome Measures: MMSE; CDR-SB; unspecified 7-item QOL scale Timing of assessments: Baseline and three week intervals throughout trial Mean QOL score was significantly better than placebo for DON 10 mg/d (P = 0.02) but not 5 Mean change in ADAS-Cog: -2.1 for the 5 mg/d DON group (95% CI: -3.59 – -1.29) and -2.7 for the 10 mg/d DON group (95% CI: -4.22 – -1.92); both were significantly better than the mean CIBIC-plus was 3.9 for the 5 mg/d DON group and 3.8.for the 10 mg/d DON group; both were significantly bett

Alzheimer classification: Mild to moderate

Groups similar at baseline: Yes

donepezil 5 mg 73.8 69 95% 4% 1% 19.39 Primary Outcome Measures: ADAS-Cog; CIBIC-plus Health Outcome Measures: mg/d Intermediate Outcome Measures: change for placebo (0.4, P < 0.001)* No differences in CDR-SB at endpoint

• • • • •

Final Report Update 1 Authors: Rogers et al. Year: 1998 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: Mean baseline MMSE • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs